Last reviewed · How we verify
Granulocyte-colony stimulating growth factor
Granulocyte-colony stimulating factor (G-CSF) stimulates the bone marrow to produce and release neutrophils, increasing white blood cell counts.
Granulocyte-colony stimulating factor (G-CSF) stimulates the bone marrow to produce and release neutrophils, increasing white blood cell counts. Used for Chemotherapy-induced neutropenia, Severe chronic neutropenia, Mobilization of peripheral blood progenitor cells for stem cell transplantation.
At a glance
| Generic name | Granulocyte-colony stimulating growth factor |
|---|---|
| Also known as | Granocyte, Neulasta |
| Sponsor | Hellenic Oncology Research Group |
| Drug class | Cytokine; Hematopoietic growth factor |
| Target | G-CSF receptor (CSF3R) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Hematology |
| Phase | Phase 3 |
Mechanism of action
G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into neutrophils. It enhances neutrophil mobilization from the bone marrow into peripheral circulation, thereby increasing absolute neutrophil counts. This mechanism is used clinically to mitigate chemotherapy-induced neutropenia and support immune recovery.
Approved indications
- Chemotherapy-induced neutropenia
- Severe chronic neutropenia
- Mobilization of peripheral blood progenitor cells for stem cell transplantation
Common side effects
- Bone pain
- Headache
- Fatigue
- Fever
- Splenomegaly
- Injection site reactions
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (PHASE1)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: